From Wikipedia, the free encyclopedia
Jump to: navigation, search

Benzphetamine (Didrex) is used short-term along with a doctor-approved, reduced-calorie diet, exercise, and behavior change program to help you lose weight. It is used in people who are significantly overweight (obese) and have not been able to lose enough weight with diet and exercise alone. Losing weight and keeping it off can reduce the many health risks that come with obesity, including heart disease, diabetes, high blood pressure, and a shorter life.

It is not known how this medication helps people to lose weight. It may work by decreasing your appetite, increasing the amount of energy used by your body, or by affecting certain parts of the brain. This medication is an appetite suppressant and belongs to a class of drugs called sympathomimetic amines.

Benzphetamine 3d.gif
Systematic (IUPAC) name
Clinical data
Trade names Didrex, Recede
AHFS/ Consumer Drug Information
  • US: X (Contraindicated)
Legal status
Routes of
Pharmacokinetic data
Protein binding 75–99%
CAS Registry Number 156-08-1 YesY
ATC code None
PubChem CID: 5311017
DrugBank DB00865 YesY
ChemSpider 4470556 YesY
UNII 0M3S43XK27 YesY
Synonyms N-benzyl-N-methylamphetamine
Chemical data
Formula C17H21N
Molecular mass 239.355 g/mol
 N (what is this?)  (verify)


Benzphetamine is a sympathomimetic amine and is classified as an anorectic. The drug's main function is to reduce appetite, which in turn reduces caloric intake. Benzphetamine may cause vivid hallucinations when abused.

Although the mechanism of action of the sympathomimetic appetite suppressants in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Amphetamine and related sympathomimetic medications (such as benzphetamine) are thought to stimulate the release of norepinephrine and/or dopamine from storage sites in nerve terminals of the lateral hypothalamic feeding center, thereby producing a decrease in appetite. This release is mediated through the binding of benzphetamine to VMAT2 and inhibiting its function, causing a release of these neurotransmitters into the synaptic cleft through their reuptake transporters. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class.


Benzphetamine is contraindicated in patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyper-thyroidism, known hypersensitivity or idiosyncrasy to sympathomimetic amines, and glaucoma. Benzphetamine should not be given to patients who are in an agitated state or who have a history of drug abuse.

Controlled substance classification[edit]

Benzphetamine is unique in its classification as a Schedule III drug in the United States. (Most members of the amphetamine family are classified in the more highly regulated Schedule II.) Benzphetamine is metabolized by the human body into amphetamine and methamphetamine, making it one of a number of drugs to undergo in vivo conversion to a substance of higher addiction and abuse potential.[1] Benzphetamine itself does not have as high abuse potential as its metabolites (Schedule III) because of the time necessary for the liver to metabolize it into amphetamine and methamphetamine, regardless of route of administration. This gives benzphetamine an inherent 'sustained-release' effect.[citation needed]


  1. ^ Musshoff F (February 2000). "Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine". Drug Metab. Rev. 32 (1): 15–44. doi:10.1081/DMR-100100562. PMID 10711406.